Cargando…

Fluids in Sepsis and Septic Shock (FISSH): protocol for a pilot randomised controlled trial

INTRODUCTION: Observational evidence suggests physiological benefits and lower mortality with lower chloride solutions; however, 0.9% saline remains the most widely used fluid worldwide. Given uncertainty regarding the association of lower chloride on mortality, it is unlikely that practice will cha...

Descripción completa

Detalles Bibliográficos
Autores principales: Rochwerg, Bram, Millen, Tina, Austin, Peggy, Zeller, Michelle, D’Aragon, Frédérick, Jaeschke, Roman, Masse, Marie-Hélène, Mehta, Sangeeta, Lamontagne, Francois, Meade, Maureen, Guyatt, Gordon, Cook, Deborah J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5642672/
https://www.ncbi.nlm.nih.gov/pubmed/28729329
http://dx.doi.org/10.1136/bmjopen-2017-017602
_version_ 1783271418189840384
author Rochwerg, Bram
Millen, Tina
Austin, Peggy
Zeller, Michelle
D’Aragon, Frédérick
Jaeschke, Roman
Masse, Marie-Hélène
Mehta, Sangeeta
Lamontagne, Francois
Meade, Maureen
Guyatt, Gordon
Cook, Deborah J
author_facet Rochwerg, Bram
Millen, Tina
Austin, Peggy
Zeller, Michelle
D’Aragon, Frédérick
Jaeschke, Roman
Masse, Marie-Hélène
Mehta, Sangeeta
Lamontagne, Francois
Meade, Maureen
Guyatt, Gordon
Cook, Deborah J
author_sort Rochwerg, Bram
collection PubMed
description INTRODUCTION: Observational evidence suggests physiological benefits and lower mortality with lower chloride solutions; however, 0.9% saline remains the most widely used fluid worldwide. Given uncertainty regarding the association of lower chloride on mortality, it is unlikely that practice will change without direct randomised clinical trial (RCT) evidence. This pilot RCT will investigate the feasibility of a large-scale trial directly comparing low chloride with high chloride fluids in patients with septic shock. METHODS AND ANALYSIS: This is a randomised, concealed, blinded parallel-group multicentre pilot trial. We will include adult critically ill patients with septic shock, defined as ongoing hypotension despite 1 L of fluid, or a serum lactate >4 mmol/L, who are within 6 hours of hospital presentation or rapid response team activation. We will exclude patients if they have an aetiology of shock other than sepsis, if they have acute burn injury, elevated intracranial pressure, intent to withdraw life support or previous enrolment in this or a competing trial. Following informed consent, patients will be randomised to a low chloride fluid strategy or a high chloride fluid strategy for the duration of their ICU stay or until 30 days postrandomisation. Clinicians, patients, families and research staff will be blinded. The primary outcome for this trial will be feasibility, assessed by consent rate, recruitment success and protocol adherence. Patient-important clinical outcomes include mortality, receipt of renal replacement therapy, intensive care unit and hospital lengths of stay and surrogate outcomes of incidence of acidosis, hyperkalaemia and acute kidney injury. ETHICS AND DISSEMINATION: This pilot trial will test the feasibility of conducting the main trial, which will examine the effect of high versus low chloride fluids in patients with septic shock on patient-important outcomes. TRIAL REGISTRATION NUMBER: NCT02748382, registered 8 April 2016. PROTOCOL DATE: 1 July 2016.
format Online
Article
Text
id pubmed-5642672
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-56426722017-10-25 Fluids in Sepsis and Septic Shock (FISSH): protocol for a pilot randomised controlled trial Rochwerg, Bram Millen, Tina Austin, Peggy Zeller, Michelle D’Aragon, Frédérick Jaeschke, Roman Masse, Marie-Hélène Mehta, Sangeeta Lamontagne, Francois Meade, Maureen Guyatt, Gordon Cook, Deborah J BMJ Open Intensive Care INTRODUCTION: Observational evidence suggests physiological benefits and lower mortality with lower chloride solutions; however, 0.9% saline remains the most widely used fluid worldwide. Given uncertainty regarding the association of lower chloride on mortality, it is unlikely that practice will change without direct randomised clinical trial (RCT) evidence. This pilot RCT will investigate the feasibility of a large-scale trial directly comparing low chloride with high chloride fluids in patients with septic shock. METHODS AND ANALYSIS: This is a randomised, concealed, blinded parallel-group multicentre pilot trial. We will include adult critically ill patients with septic shock, defined as ongoing hypotension despite 1 L of fluid, or a serum lactate >4 mmol/L, who are within 6 hours of hospital presentation or rapid response team activation. We will exclude patients if they have an aetiology of shock other than sepsis, if they have acute burn injury, elevated intracranial pressure, intent to withdraw life support or previous enrolment in this or a competing trial. Following informed consent, patients will be randomised to a low chloride fluid strategy or a high chloride fluid strategy for the duration of their ICU stay or until 30 days postrandomisation. Clinicians, patients, families and research staff will be blinded. The primary outcome for this trial will be feasibility, assessed by consent rate, recruitment success and protocol adherence. Patient-important clinical outcomes include mortality, receipt of renal replacement therapy, intensive care unit and hospital lengths of stay and surrogate outcomes of incidence of acidosis, hyperkalaemia and acute kidney injury. ETHICS AND DISSEMINATION: This pilot trial will test the feasibility of conducting the main trial, which will examine the effect of high versus low chloride fluids in patients with septic shock on patient-important outcomes. TRIAL REGISTRATION NUMBER: NCT02748382, registered 8 April 2016. PROTOCOL DATE: 1 July 2016. BMJ Publishing Group 2017-07-20 /pmc/articles/PMC5642672/ /pubmed/28729329 http://dx.doi.org/10.1136/bmjopen-2017-017602 Text en © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
spellingShingle Intensive Care
Rochwerg, Bram
Millen, Tina
Austin, Peggy
Zeller, Michelle
D’Aragon, Frédérick
Jaeschke, Roman
Masse, Marie-Hélène
Mehta, Sangeeta
Lamontagne, Francois
Meade, Maureen
Guyatt, Gordon
Cook, Deborah J
Fluids in Sepsis and Septic Shock (FISSH): protocol for a pilot randomised controlled trial
title Fluids in Sepsis and Septic Shock (FISSH): protocol for a pilot randomised controlled trial
title_full Fluids in Sepsis and Septic Shock (FISSH): protocol for a pilot randomised controlled trial
title_fullStr Fluids in Sepsis and Septic Shock (FISSH): protocol for a pilot randomised controlled trial
title_full_unstemmed Fluids in Sepsis and Septic Shock (FISSH): protocol for a pilot randomised controlled trial
title_short Fluids in Sepsis and Septic Shock (FISSH): protocol for a pilot randomised controlled trial
title_sort fluids in sepsis and septic shock (fissh): protocol for a pilot randomised controlled trial
topic Intensive Care
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5642672/
https://www.ncbi.nlm.nih.gov/pubmed/28729329
http://dx.doi.org/10.1136/bmjopen-2017-017602
work_keys_str_mv AT rochwergbram fluidsinsepsisandsepticshockfisshprotocolforapilotrandomisedcontrolledtrial
AT millentina fluidsinsepsisandsepticshockfisshprotocolforapilotrandomisedcontrolledtrial
AT austinpeggy fluidsinsepsisandsepticshockfisshprotocolforapilotrandomisedcontrolledtrial
AT zellermichelle fluidsinsepsisandsepticshockfisshprotocolforapilotrandomisedcontrolledtrial
AT daragonfrederick fluidsinsepsisandsepticshockfisshprotocolforapilotrandomisedcontrolledtrial
AT jaeschkeroman fluidsinsepsisandsepticshockfisshprotocolforapilotrandomisedcontrolledtrial
AT massemariehelene fluidsinsepsisandsepticshockfisshprotocolforapilotrandomisedcontrolledtrial
AT mehtasangeeta fluidsinsepsisandsepticshockfisshprotocolforapilotrandomisedcontrolledtrial
AT lamontagnefrancois fluidsinsepsisandsepticshockfisshprotocolforapilotrandomisedcontrolledtrial
AT meademaureen fluidsinsepsisandsepticshockfisshprotocolforapilotrandomisedcontrolledtrial
AT guyattgordon fluidsinsepsisandsepticshockfisshprotocolforapilotrandomisedcontrolledtrial
AT cookdeborahj fluidsinsepsisandsepticshockfisshprotocolforapilotrandomisedcontrolledtrial